Published in Cancer Treat Rev on December 16, 2011
Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer (2013) 1.54
Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J (2013) 1.17
Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol (2014) 1.16
Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One (2013) 1.16
MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J Cancer (2013) 1.07
Endocrine disruptors and the breast: early life effects and later life disease. J Mammary Gland Biol Neoplasia (2013) 1.07
Role of microRNAs in breast cancer. Cancer Biol Ther (2013) 1.07
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer (2014) 0.94
Effects of age on the detection and management of breast cancer. Cancers (Basel) (2015) 0.94
Increased expression and copy number amplification of LINE-1 and SINE B1 retrotransposable elements in murine mammary carcinoma progression. Oncotarget (2013) 0.93
Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep (2015) 0.91
Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects. PLoS One (2013) 0.90
Long non-coding RNAs as prognostic markers in human breast cancer. Oncotarget (2016) 0.89
Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J Biol Chem (2013) 0.89
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs (2015) 0.88
Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev (2015) 0.88
Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol (2016) 0.86
In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness. Mol Cancer (2013) 0.85
Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Front Endocrinol (Lausanne) (2015) 0.85
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget (2016) 0.85
Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med (2016) 0.84
Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy. Crit Rev Oncol Hematol (2013) 0.84
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res (2015) 0.84
Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Exp Biol Med (Maywood) (2012) 0.84
STAT signaling in different breast cancer sub-types. Mol Cell Endocrinol (2013) 0.83
Expression and prognostic role of SGTA in human breast carcinoma correlates with tumor cell proliferation. J Mol Histol (2014) 0.82
A novel link between the HER2-Akt and MDM2-p53 pathways via CSN6. Cell Cycle (2012) 0.82
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget (2016) 0.82
Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. Hum Mol Genet (2015) 0.81
Age-associated prognostic and predictive biomarkers in patients with breast cancer. Oncol Lett (2017) 0.81
The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells. J Cell Biochem (2015) 0.81
Identification of collaborative driver pathways in breast cancer. BMC Genomics (2014) 0.81
Biomarker identification in breast cancer: Beta-adrenergic receptor signaling and pathways to therapeutic response. Comput Struct Biotechnol J (2013) 0.81
Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells. Mol Carcinog (2014) 0.81
Foxa1 is essential for mammary duct formation. Genesis (2016) 0.80
Revealing the Complexity of Breast Cancer by Next Generation Sequencing. Cancers (Basel) (2015) 0.80
Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Res (2016) 0.80
miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. Int J Mol Sci (2015) 0.80
The molecular genomics of metastatic brain tumours. OA Mol Oncol (2013) 0.80
The highly expressed 5'isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. BMC Genomics (2016) 0.79
Immunohistochemical expression of CXCR4 on breast cancer and its clinical significance. Anal Cell Pathol (Amst) (2015) 0.79
Correlation between PDZK1, Cdc37, Akt and breast cancer malignancy: the role of PDZK1 in cell growth through Akt stabilization by increasing and interacting with Cdc37. Mol Med (2014) 0.79
The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer. Int J Mol Sci (2016) 0.79
Imagine a world without cancer. BMC Cancer (2014) 0.79
The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Sci Rep (2017) 0.78
Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma. BMC Cancer (2015) 0.78
Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells. Oncotarget (2015) 0.78
Functional characterization of breast cancer using pathway profiles. BMC Med Genomics (2014) 0.78
Distinct breast cancer subtypes in women with early-onset disease across races. Am J Cancer Res (2014) 0.78
Wnt signaling in triple-negative breast cancer. Oncogenesis (2017) 0.78
Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer. Mol Cell Proteomics (2015) 0.77
Progression of luminal breast tumors is promoted by ménage à trois between the inflammatory cytokine TNFα and the hormonal and growth-supporting arms of the tumor microenvironment. Mediators Inflamm (2013) 0.77
Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study. PLoS One (2013) 0.77
RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells. Oncotarget (2015) 0.77
Mild hyperthermia influence on Herceptin(®) properties. Radiol Oncol (2015) 0.77
High nuclear level of Vav1 is a positive prognostic factor in early invasive breast tumors: a role in modulating genes related to the efficiency of metastatic process. Oncotarget (2014) 0.77
From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression. BMC Syst Biol (2015) 0.76
The C/EBPδ protein is stabilized by estrogen receptor α activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer. Oncogene (2016) 0.76
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women. Front Oncol (2016) 0.76
Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2. PLoS One (2017) 0.76
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer. Oncoscience (2015) 0.76
Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5. Genet Mol Biol (2014) 0.76
Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study. Breast Cancer Res Treat (2015) 0.76
Beta protein 1 homeoprotein induces cell growth and estrogen-independent tumorigenesis by binding to the estrogen receptor in breast cancer. Oncotarget (2016) 0.75
Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line. PLoS One (2016) 0.75
Alteration of GLIS3 gene expression pattern in patients with breast cancer. Adv Biomed Res (2016) 0.75
AMP-activated protein kinase and energy balance in breast cancer. Am J Transl Res (2017) 0.75
Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer? Iran J Cancer Prev (2016) 0.75
SOX7 co-regulates Wnt/β-catenin signaling with Axin-2: both expressed at low levels in breast cancer. Sci Rep (2016) 0.75
Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients. Oncol Lett (2016) 0.75
A Methodology for Cancer Therapeutics by Systems Pharmacology-Based Analysis: A Case Study on Breast Cancer-Related Traditional Chinese Medicines. PLoS One (2017) 0.75
Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. Sci Rep (2016) 0.75
Quercetin induces apoptosis and cell cycle arrest in triple-negative breast cancer cells through modulation of Foxo3a activity. Korean J Physiol Pharmacol (2017) 0.75
Controllable drug uptake and nongenomic response through estrogen-anchored cyclodextrin drug complex. Int J Nanomedicine (2015) 0.75
A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer. Sci Rep (2017) 0.75
Immunoprofile from tissue microarrays to stratify familial breast cancer patients. Oncotarget (2015) 0.75
Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors. Mol Ther Oncolytics (2016) 0.75
Cx26 knockout predisposes the mammary gland to primary mammary tumors in a DMBA-induced mouse model of breast cancer. Oncotarget (2015) 0.75
G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis. EBioMedicine (2016) 0.75
Association between molecular subtypes and lymph node status in invasive breast cancer. Int J Clin Exp Pathol (2014) 0.75
Determining breast cancer histological grade from RNA-sequencing data. Breast Cancer Res (2016) 0.75
Overexpression of Raf-1 in basal-like carcinoma of the breast: correlation with clinicopathology and prognosis. Contemp Oncol (Pozn) (2014) 0.75
The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus. Transl Oncogenomics (2016) 0.75
Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases. Oncotarget (2016) 0.75
Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer. Cancer Med (2016) 0.75
Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells. Oncotarget (2016) 0.75
Ancestry as a potential modifier of gene expression in breast tumors from Colombian women. PLoS One (2017) 0.75
A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer. Transl Oncol (2017) 0.75
A pathways-based prediction model for classifying breast cancer subtypes. Oncotarget (2017) 0.75
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol (2011) 7.10
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst (2008) 3.60
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 3.07
Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med (2010) 2.99
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol (2005) 2.54
Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol (2012) 2.05
Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective. Expert Rev Pharmacoecon Outcomes Res (2014) 1.99
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol (2007) 1.93
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res (2010) 1.81
Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev (2010) 1.79
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res (2006) 1.70
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol (2009) 1.68
NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res (2002) 1.57
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat (2010) 1.50
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res (2009) 1.43
[Epidemiological study of the GEICAM group about breast cancer in Spain (1990-1993): El Alamo project]. Med Clin (Barc) (2004) 1.41
Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res (2007) 1.34
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol (2009) 1.33
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics (2011) 1.32
Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal (2007) 1.29
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat (2008) 1.25
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol (2010) 1.10
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clin Cancer Res (2014) 1.06
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol (2013) 1.05
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology (2003) 1.01
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res (2012) 1.01
High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist (2012) 0.99
The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat (2012) 0.99
High stability of microRNAs in tissue samples of compromised quality. Virchows Arch (2013) 0.98
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res Treat (2011) 0.97
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. Breast Cancer Res Treat (2010) 0.97
Genetic polymorphisms in DNA repair and oxidative stress pathways associated with malignant melanoma susceptibility. Eur J Cancer (2011) 0.96
Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population. BMC Cancer (2013) 0.95
MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in southern European populations: results from a meta-analysis. Eur J Cancer (2012) 0.95
Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat (2009) 0.93
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res (2013) 0.93
Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. Clin Cancer Res (2002) 0.92
Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. Cancer Treat Rev (2008) 0.92
Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects. PLoS One (2013) 0.90
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res (2009) 0.89
A customized pigmentation SNP array identifies a novel SNP associated with melanoma predisposition in the SLC45A2 gene. PLoS One (2011) 0.88
MicroRNAs in Breast Cancer: One More Turn in Regulation. Curr Drug Targets (2016) 0.87
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist (2012) 0.87
Trastuzumab in small tumours and in elderly women. Cancer Treat Rev (2013) 0.87
Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity. J Acad Nutr Diet (2016) 0.85
MicroRNA profile in very young women with breast cancer. BMC Cancer (2014) 0.85
Nitric oxide triggers mammary gland involution after weaning: remodelling is delayed but not impaired in mice lacking inducible nitric oxide synthase. Biochem J (2010) 0.85
Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer. Melanoma Res (2009) 0.84
Nitration of cathepsin D enhances its proteolytic activity during mammary gland remodelling after lactation. Biochem J (2009) 0.84
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer (2014) 0.83
Current perspectives of treatment of ductal carcinoma in situ. Cancer Treat Rev (2010) 0.83
Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes? Breast (2011) 0.82
Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treat Rev (2007) 0.81
Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol (2009) 0.80
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. Expert Rev Pharmacoecon Outcomes Res (2013) 0.80
Oxidative stress in susceptibility to breast cancer: study in Spanish population. BMC Cancer (2014) 0.79
Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist (2011) 0.79
An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer. Breast (2013) 0.79
Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival. Mol Cell Biochem (2013) 0.78
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme. Cancer Treat Rev (2005) 0.78
rs12512631 on the group specific complement (vitamin D-binding protein GC) implicated in melanoma susceptibility. PLoS One (2013) 0.77
Impact of a mammography screening programme on the breast cancer population of the Region of Valencia (Spain). Clin Transl Oncol (2008) 0.77
NF-ĸB as node for signal amplification during weaning. Cell Physiol Biochem (2011) 0.77
Supportive care for patients with early breast cancer. Clin Transl Oncol (2010) 0.77
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Oncologist (2016) 0.76
A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Clin Breast Cancer (2003) 0.76
In response: Genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res (2015) 0.75
Evolution of tumour biology upon progression. Do we know our enemy? Clin Transl Oncol (2012) 0.75
Identification of candidate polymorphisms on stress oxidative and DNA damage repair genes related with clinical outcome in breast cancer patients. Int J Mol Sci (2012) 0.75
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. Clin Transl Oncol (2008) 0.75
Time-to-progression in breast cancer: a stratification model for clinical trials. Breast (2007) 0.75
[Neoadjuvant therapy for operable breast-cancer]. Med Clin (Barc) (2006) 0.75
The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trials. Clin Breast Cancer (2007) 0.75
[Effect of neoadjuvant chemotherapy on the results of resection of colorectal liver metastases]. Cir Esp (2007) 0.75
Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer. Anticancer Res (2010) 0.75
Outcome differences between patients with node-negative breast cancer classified according to the st. Gallen risk categories. Clin Breast Cancer (2009) 0.75
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. Curr Cancer Drug Targets (2016) 0.75